The USPTO has announced a further delay of the fee for patent applications that are not filed in DOCX format. Originally set to take effect January 1, 2022, and then delayed to January 1, 2023, the USPTO now has delayed the effective date to April 3, 2023. This means applicants and legal teams returning from winter holiday vacations won’t be forced to file utility patent applications in DOCX format or pay an additional $400 (large entity), but will have a few more months to get comfortable with the DOCX filing and validation process.
As set forth in the Federal Register Notice, applicants are “strongly encouraged” to begin filing patent applications in DOCX format now, before the new fee takes effect. The USPTO has offered and continues to offer DOCX training sessions and other resources.
Disclaimer
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.
Author(s)
Related Insights
25 April 2024
On Trial
A Trial Lawyer’s Trial Lawyer: Paul Callan On Trial
In this episode of On Trial, host Christopher DeGennaro sits down with seasoned trial lawyer and CNN legal commentator Paul Callan, former deputy chief of the Brooklyn District Attorney’s Office, with 30 years’ experience as a trial lawyer.
25 April 2024
Health Care Law Today
New Favorable OIG Advisory Opinion Allows Patient Assistant Programs Funded by Drug Manufacturers
The Office of Inspector General recently issued a new favorable advisory opinion regarding patient assistance programs for 12 specific disease funds.
24 April 2024
Health Care Law Today
FDA Continues to Take Stance That it Will Not Issue CBD Rules
The FDA recently doubled down on its January 26, 2023 position that existing regulatory pathways for foods and dietary supplements are not appropriate to manage the risks of CBD and a new regulatory pathway is needed.